Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and. | June 7, 2023
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have received a consensus rating of “Hold” from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to […]
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have earned a consensus recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 14,180,000 shares, a decrease of 20.3% from the April 30th total of 17,790,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio […]
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) saw a large decrease in short interest in May. As of May 15th, there was short interest totalling 14,180,000 shares, a decrease of 20.3% from the April 30th total of 17,790,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 10.0 days. […]